Patients with coronavirus disease 2019 (n= 74).
Convalescent plasma (n= 59).
Standard plasma (n= 15).
At baseline, mean (SD) Acute Physiology and Chronic Health Evaluation II score (23.4 [5.6] and 22.5 [6.6]), percent of patients intubated (19% and 20%), and median (interquartile range) days from symptom onset to randomization of 9 (6-18) and 9 (6-15), were similar in the convalescent plasma versus standard plasma arms, respectively. Convalescent plasma had high neutralizing activity (median [interquartile range] titre 1:526 [1:359-1:786]) and its administration increased antibodies to severe acute respiratory syndrome coronavirus 2 by 14.4%, whereas standard plasma administration led to an 8.6% decrease. No difference was observed for ventilator-free days through 28 days: median (interquartile range) of 28 (2-28) versus 28 (0-28) for the convalescent plasma and standard plasma groups, respectively. A greater than or equal to 2 point improvement in the World Health Organization scale was achieved by 20% of subjects in both arms. All-cause mortality through 90 days was numerically lower in the convalescent plasma versus standard plasma groups (27% vs 33%) but did not achieve statistical significance.